PDCD1 and colorectal carcinoma: Accordingly, in 2017, the anti-PD-1 inhibitors pembrolizumab (KeytrudaVR, Merck) and nivolumab (OpdivoVR, Bristol-Myers Squibb) have been approved by the Food and Drug Administration (FDA) for the treatment of patients with dMMR/MSI-H CRC.